Showing results (141-150 of 152) with videos related to

Sort By:
Pageof 16
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast CancerMatteo Lambertini, Marcello Ceppi, Richard A Anderson, et al.
NPJ Breast Cancer|May 24, 2022
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trialsSaranya Chumsri, Zhuo Li, Daniel J Serie, et al.
Applied Clinical Informatics|September 11, 2024
Developing PRISM: A Pragmatic Institutional Survey and Bench Marking Tool to Measure Digital Research Maturity of Cancer CentersCarlos Berenguer Albiñana, Matteo Pallocca, Hayley Fenton, et al.
Breast Cancer Research : BCR|December 5, 2019
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2<sup>+</sup> breast cancerSamuel A Jacobs, André Robidoux, Jame Abraham, et al.
Breast Cancer Research : BCR|January 24, 2020
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancerSamuel A Jacobs, André Robidoux, Jame Abraham, et al.
The Lancet. Oncology|August 19, 2014
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseEvandro de Azambuja, Andrew P Holmes, Martine Piccart-Gebhart, et al.
Journal of the National Cancer Institute|July 5, 2022
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant TrastuzumabFrancesca Ligorio, Serena Di Cosimo, Paolo Verderio, et al.
Cancers|April 3, 2021
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort StudySerena Di Cosimo, Barbara Tagliaferri, Daniele Generali, et al.
Lancet (London, England)|April 6, 2024
3-year invasive disease-free survival with chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trialJosé Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego, et al.
Journal of the National Cancer Institute. Monographs|June 12, 2015
International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013)Vito Amoroso, Daniele Generali, Thomas Buchholz, et al.
Pageof 16